



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION COMMENCES HEALTHY HUMAN TRIALS & RECEIVES ISO 13485 CERTIFICATION

- *EMvision Medical Devices raises AUD\$6M in oversubscribed initial public offer supported by institutional investors, clinicians and family offices.*
- *Funding will be used to advance and accelerate the company's brain scanner program for the rapid diagnosis of stroke, and demonstrate the device's performance and safety through clinical trials.*
- *Healthy human trials are currently underway to evaluate how the clinical prototype and algorithms perform in a real world environment.*
- *ISO 13485 Certification has also been received from TÜV Rheinland, which is the corporate foundation for obtaining European CE Mark and Australian Therapeutic Goods Administration (TGA) approval.*

EMvision Medical Devices Limited (ASX: EMV) ("EMvision" or the "Company") is pleased to announce it will commence trading on the Australian Securities Exchange ("ASX") under the code "EMV" at 2:00pm AEDT today, following the successful completion of its oversubscribed initial public offering.

The Company issued 24,000,000 shares at \$0.25 each, giving it a market capitalisation of \$14.4 million and raising AUD \$6,000,000, with strong support from institutional investors, clinicians and family offices.

In partnership with the University of Queensland, EMvision is developing a portable, cost effective, non-invasive brain scanner to monitor and help diagnosis of brain injuries and stroke by creating rapid 3D images of the brain.

EMvision CEO Dr Ron Weinberger said; "After 10 years of technology research and development in electromagnetic microwave imaging at the University of Queensland, this funding will allow the Company to develop its device and conduct hospital trials. Device safety and efficacy will be demonstrated in a clinical environment."

The device has potential for use in stroke wards, intensive care units, ambulances and remote locations providing decision support and monitoring to the patients, regardless of where they are.

This is a significant advancement over today's stationary, complex and expensive stroke imaging technologies such as CT and MRI. These technologies are reliant on the patient being physically relocated to radiology departments, leading to potential delays for diagnosis and treatment as well as workflow challenges for healthcare staff.

"Despite recent advances in life-saving treatments for acute stroke only a fraction of stroke patients qualify for intervention because they do not present and have their condition diagnosed early enough. This is why reducing the time of diagnosis and treatment makes our brain scanner an attractive proposition for the healthcare industry" said Dr Weinberger.




Image: Concept render of EMvision's brain scanner that the Company is working towards.

EMvision was awarded a \$2.6 million Cooperative Research Centre project grant from the Government of the Commonwealth of Australia in late 2017, and, through the grant process, has established key academic, clinical and industry relationships that will assist in the advancement and commercialisation of the Company's brain scanner program. These partners have also committed to provide a further \$910,000 in grant funds to EMvision.

These include GE Healthcare, a US\$19 billion healthcare business of GE (NYSE:GE), the University of Queensland which is one of the world's top 10 universities for biotechnology, and The Queensland Government Metro South Hospital and Health Service operating at the Princess Alexandra Hospital, one of Australia's leading academic and research centres.

"We are excited to be working closely with these groups who share our passion and commitment to developing a ground breaking solution for medical professionals. We aim to quickly identify and monitor stroke, and reduce hospital costs and strain stroke causes on our healthcare systems" said Dr Ron Weinberger.

EMvision is also pleased to announce that the Company has received formal ISO 13485 Certification from TÜV Rheinland. This certifies that EMvision has established and applies a quality management system for medical devices for the design and development of body imaging systems.

ISO 13485 is an essential requirement in obtaining European CE Mark and Australian Therapeutic Goods Administration (TGA) approval. The completion of the second stage audit by TÜV Rheinland and obtaining this certification is an important milestone for the Company as we approach our clinical trials.

In addition, the Company advises that healthy human trials are currently underway to evaluate how the clinical prototype and system perform in a real-world environment. Results from the healthy human trials are expected to be completed in early 2019. Following the acquisition of positive safety data from the healthy human trials, the Company will then run a pilot clinical trial at Brisbane's Princess Alexandra Hospital to collect data from patients with diagnosed ischaemic and haemorrhagic stroke, with confirmatory CT or MRI images. This pilot clinical trial is expected to commence in second half 2019.

[ENDS]

For further information, media or investor enquires, please contact:

Michael Wills
Investor Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

ABOUT EMVISION

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997.